Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.
The chart below shows how we grade Latigo Biotherapeutics (LTGO) across the board compared to its closest peers.
Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.
See how Latigo Biotherapeutics compares to its peers in these key performance metrics from Benzinga Rankings.
Below, you can see that analysts are estimating a 12-month price target range of $36.00 - $50.00 with an average of $45.33
Recent Ratings for Latigo Biotherapeutics (LTGO)
